文献速递乳腺癌放疗放疗物理与技术

HypoG-01 III期试验基于个体DICOM数据的放疗质量保证综合分析

Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial.
PubMed 文献 · Radiother Oncol · 2025-10-30

该研究对HypoG-01 III期试验中前瞻性收集的个体放疗计划进行质量保证分析,覆盖29个中心1,093例乳腺癌患者。结果显示处方剂量符合率99.2%,但靶区勾画和计划约束依从性存在较大中心内和中心间异质性,强调严格QA的必要性。

要点

  • 处方剂量符合率高达99.2%,但CTVp_乳腺仅75.1%符合方案约束。
  • 心脏、同侧肺和对侧乳腺约束符合率分别为93.7%、81.2%和63.4%。
  • 勾画和计划存在较大中心内与中心间差异,需严格QA框架。

核心结论

  • 观察到的勾画和放疗计划异质性提示需要严格的质量保证。
  • QA分析显示两治疗组结果可比,证实HypoG-01结局的稳健性,并为未来放疗试验提供可扩展框架。

研究设计与样本

  • HypoG-01 III期随机试验将适合局部区域放疗的乳腺癌患者随机分配至40 Gy/15次/3周或50 Gy/25次/5周。
  • 前瞻性收集29个中心2016年9月至2020年3月入组的1,093例患者(占符合方案人群89.5%)的个体DICOM-RT计划进行QA分析。
  • 依据ESTRO指南预设体积定义和剂量学约束,所有中心接受前瞻性QA包括系统性DICOM-RT传输,并进行方案依从性及中心内和中心间变异的描述性分析。

主要发现

  • 610例患者接受保乳手术,其中541例接受瘤床推量,序贯推量占69.9%,同步推量占30.1%。
  • 仅76例(6.9%)患者采用屏气治疗。
  • 99.2%的计划处方剂量符合方案。
  • 预设危及器官勾画率范围为95.2%至100%。
  • CTVp_乳腺、CTVp_胸壁、CTVp_瘤床和CTVn符合方案约束的比例分别为75.1%、42.9%、90.4%和67.5%至87.7%。

关键数值与推荐

  • 处方剂量符合方案的比例为99.2%。
  • CTVp_乳腺符合方案约束的比例为75.1%,CTVp_胸壁为42.9%,CTVp_瘤床为90.4%,CTVn为67.5%至87.7%。
  • 已勾画危及器官中,心脏约束符合率为93.7%,同侧肺为81.2%,对侧乳腺为63.4%,两治疗组间无明显差异。
  • 瘤床推量中序贯推量占69.9%,同步推量占30.1%。

临床怎么用

  • 开展乳腺癌放疗临床试验时应实施前瞻性QA,包括系统性DICOM-RT数据传输和预设体积定义与剂量学约束。
  • 需关注靶区勾画和计划约束依从性,尤其是胸壁CTV和区域淋巴结CTV,以减少中心内和中心间变异。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Quality Assurance (QA) in radiation therapy (RT) trials is crucial. We report here the QA analysis of prospectively collected individual RT-plans in the HypoG-01 phase III trial. METHODS: HypoG-01 randomised breast cancer patients indicated for locoregional RT to 40 Gy/15 fractions/3 weeks versus 50 Gy/25 fractions/5 weeks. Volume definitions following ESTRO guidelines, and dosimetric constraints were predefined. All centres underwent a prospective QA, including systematic DICOM-RT transfer. Descriptive analyses of protocol compliance, and intra and inter-centre variations were conducted. RESULTS: RT-plans from 1,093 patients (89.5% of the per-protocol population), included between September 2016 and March 2020, were retrieved from 29 centres. Overall, 610 patients underwent breast-conservation surgery, with 541 receiving a tumour-bed boost, either sequentially (69.9%) or simultaneously (30.1%). Only 76 patients (6.9%) were treated using breath-hold. Most plans (99.2%) had compliant prescribed doses. Delineation rates of pre-specified organs at risk ranged from 95.2% and 100%. Regarding treatment planning, 75.1% of the CTVp_breast, 42.9% of the CTVp_thoracic wall, 90.4% of the CTVp_tumour bed, and 67.5-87.7% of the CTVn complied with protocol constraints. For delineated OARs, constraints were met in 93.7% for heart, 81.2% for ipsilateral lung, and 63.4% for contralateral breast without obvious differences between arms; however, large intra and inter-centre variability was noted. CONCLUSION: The observed heterogeneity in contouring and RT-planning highlights the need for rigorous QA. Our QA analysis finds comparable results in both arms, which confirms the robustness of HypoG-01 outcomes, and offers a scalable framework for the conduct of future RT trials.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Brion T, Balde M, Allodji R, et al. Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial. Radiother Oncol. 2025. PMID: 41173355. doi:10.1016/j.radonc.2025.111202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。